Citations

Clear

1820 citation(s) found for "Israel, E".

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Rabinovici, Gil D. , Knopman, David S., Donohoe, Kevin, Herscovitch, Peter, Kuo, Phillip H. , Lingler, Jennifer H. , Price, Julie C. , Salloway, Stephen P., Weber, Christopher J., Carrillo, María C. , Johnson, Keith A. , Rabinovici, Gil D , Arbizu, Javier , Benzinger, Tammie L.S. , Hansson, Oskar , Minoshima, Satoshi , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | January 8, 2025 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14338 | PMID 39776249 Get It

Abstract INTRODUCTION The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. METHODS The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand‐alone modalities. RESULTS For amyloid PET, seven scenarios were rated as appropriate, two as uncertain, and eight as rarely appropriate. For tau PET, five scenarios were rated as appropriate, six as uncertain, and six as rarely appropriate. DISCUSSION AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer's disease. Highlights A multidisciplinary workgroup convened by the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging updated the appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. The goal of these updated AUC is to assist clinicians in identifying clinical scenarios in which amyloid or tau PET may be useful for guiding the diagnosis and management of patients who have, or are at risk for, cognitive decline These updated AUC are intended for dementia specialists who spend a significant proportion of their clinical effort caring for patients with cognitive complaints, as well as serve as a general reference for a broader audience interested in implementation of amyloid and tau PET in clinical practice.
DNA topological regulation by topoisomerase IIβ-DNA-PK interaction is important for controlled hypoxia-inducible gene expression
Bunch, Heeyoun , Park, Jihye , Solverson, Jasper K., Lee, Jeongho, Yoo, Ji-Seung , Jang, Jaeyeon, Yoon, Young-Ran, Schellenberg, Matthew J. , Jung, Inuk, Calderwood, Stuart K. , Kang, Keunsoo, Davis, Anthony J , Solverson, Jasper K., Lee, Jeongho, Yoo, Ji-Seung , Lu, Huiming , Jang, Jaeyeon, Jeon, Jae-Han , Jung, Inuk, Kang, Keunsoo, Davis, Anthony J.

Mayo Clinic

No container title available | January 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.06.631366 | PMID 41993293 Get It

ABSTRACT Hypoxic stress responses are essential for cellular and organismal survival and drive gene regulation across diverse biological pathways, including cell cycle progression and energy metabolism. Here, we show that topoisomerase IIβ (TOP2B) regulates DNA topology and transcription of hypoxia-inducible genes (HIGs) in a DNA-dependent protein kinase (DNA-PK)-dependent manner. Integrated cellular, biochemical, and genomic analyses reveal an antagonistic yet correlated relationship between TOP2B and DNA-PK activities. Under normoxic conditions, TOP2B associates with HIGs and represses transcription by suppressing DNA negative supercoiling formation and accessibility. Under hypoxic exposure, TOP2B dissociates from HIGs, while DNA-PK and HIF1α are recruited to activate HIGs. Notably, DNA-PK is required for the repressive function of TOP2B, as DNA-PK knockout abrogates TOP2B release and activity, resulting in elevated expression of a number of HIGs. Mechanistically, DNA-PK phosphorylates TOP2B at T1403, stimulating its catalytic activity to restrain DNA unwinding and accessibility, thereby suppressing HIG transcription. Collectively, these findings identify a novel role for TOP2B and DNA-PK-mediated regulation of TOP2B as key transcriptional regulators of HIG expression. We propose that phosphorylation-dependent modulation of TOP2B activity is coordinated with transcriptional states and determines DNA topology to regulate Pol II transcription.
Updated Geriatrics Competencies for Graduating Medical Students: Training Physicians to Provide Age-Friendly Care
Schwartz, Andrea Wershof , Sehgal, Mandi , Dawson, Catherine M. P. , Granville, Lisa , Powers, Becky , Shah, Amit , Sullivan, Amy , Leipzig, Rosanne M. , Powers, Becky B , Shah, Amit A , Sullivan, Amy M , Schwartz, Andrea Wershof

Mayo Clinic

Academic Medicine | January 3, 2025 | Volume: 100 | Issue: 5 | Pages: 592-599

10.1097/acm.0000000000005958 | PMID 39752580 Get It

Abstract Purpose Medical student education in geriatrics is a critical need for every doctor-in-training as the population ages, with fewer than 7,000 geriatricians, and older patients, who now approach 20% of the U.S. population, having unique health care needs. This study presents the updated competencies in geriatrics for graduating medical students, framed by the Geriatrics 5Ms (Mind, Mobility, Medications, Multicomplexity, and What Matters Most). Method From 2019–2022, a working group of the American Geriatrics Society (AGS) drafted the updated medical student geriatrics education competencies, using a modified Delphi approach. The working group reviewed the literature, conducted an initial survey of working group members, and drafted and refined proposed updates to the competencies. The 27 resulting competencies were disseminated as a national survey to geriatrics experts and medical school education deans. Following the national survey, the competencies were updated and presented at the 2021 AGS Annual Scientific Meeting and open to public comment before they were finalized. Results The 27 updated geriatrics competencies for medical students included several new competencies, such as a focus on health equity, frailty, deprescribing, and patient priorities. A total of 211 respondents completed the national survey, including geriatrics experts (187/398, response rate: 47.0%) and education deans (24/191, response rate: 12.6%). All 27 proposed competencies met the predetermined threshold of 70% cumulative agreement, with a range of 93.0% (174/187) to 100% (187/187) among geriatrics experts and 87.5% (21/24) to 100% (24/24) among education deans. Conclusions The updated Geriatrics Competencies for Graduating Medical Students met with broad agreement among the geriatrics experts and medical school education deans who responded to the national survey. By focusing on the Geriatrics 5Ms, the competencies highlight key knowledge and skills graduating medical students need for the first day of internship to be prepared to deliver age-friendly care to older adults under their care.
International Consensus Guidance for the Management of Glucocorticoid Related Complications in Neuromuscular Disease
Bacher, Corey, Narayanaswami, Pushpa , Bromberg, Mark B. , Buttgereit, Frank , Dodig, Dubravka , Marshall, John K., Mitchell, Sara, Tosh, Pritish K. , Sinha, Partha, Laughlin, Ruple S. , Kassardjian, Charles D. , Narayanswami, Pushpa , Buttgereit, Frank , Flanagan, Eoin P. , Gottlieb, Chloe , Marshall, John K. , McCoy, Rozalina G.

Mayo Clinic

Muscle & Nerve | January 3, 2025 | Volume: 71 | Issue: 3 | Pages: 309-316

10.1002/mus.28328 | PMID 39749741 Get It

ABSTRACTIntroduction/AimsGlucocorticoid (GC)‐related adverse reactions and risks are commonly seen during the treatment of immune‐mediated and inflammatory neuromuscular disorders. There is wide variation in the management of associated complications. The aim of this study is to develop international consensus guidance on the management of GC‐related complications in neuromuscular disorders.MethodsThrough the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), an international task force of 15 experts was convened to develop clinical guidance for the management of GC‐related complications in neuromuscular patients. The RAND/UCLA appropriateness method (RAM) was used to develop consensus guidance statements. Initial guidance statements were crafted after a thorough literature review and were modified after anonymous panel input, with up to three rounds of voting via email to achieve consensus.ResultsStatements were developed and achieved consensus for general care, monitoring of patients while on GC, osteoporosis prevention, vaccinations, infection screening, and Pneumocystis jiroveci pneumonia prophylaxis. A multidisciplinary approach to the management of GC‐related complications was emphasized.DiscussionThese formal consensus statements provide guidance to clinicians who use GC in the treatment of neuromuscular diseases regarding prevention and management of the more common associated adverse events and risks that arise with long and short‐term GC use and serve as a springboard for investigation and updates.
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study
Topp, Max S. , Matasar, Matthew J. , Allan, John N. , Ansell, Stephen M. , Barnes, Jeffrey A. , Arnason, Jon , Michot, Jean‐Marie , Goldschmidt, Neta , Abadi, Uri , Avivi, I., Cheng, Yuan , Flink, Dina M., Brouwer‐Visser, Jurriaan , Chaudhry, Aafia, Ambati, Srikanth, Crombie, Jennifer L. , Matasar, Matthew , O’Brien, Susan , Zhu, Min , Mohamed, Hesham

Mayo Clinic

Blood | December 30, 2024 | Volume: 145 | Issue: 14 | Pages: 1498-1509

10.1182/blood.2024027044 | PMID 39786390 Get It

Abstract Patients with relapsed/refractory diffuse large B-cell lymphoma progressing after chimeric antigen receptor T-cell (CAR-T) therapy have dismal outcomes. The prespecified post–CAR-T expansion cohort of the ELM-1 study investigated the efficacy and safety of odronextamab, a CD20×CD3 bispecific antibody, in patients with disease progression after CAR-Ts. Sixty patients received IV odronextamab weekly for 4 cycles followed by maintenance until progression. The primary end point was objective response rate (ORR) by independent central review. The median number of prior lines of therapy was 3 (range, 2-9), 71.7% were refractory to CAR-Ts, and 48.3% relapsed within 90 days of CAR-T therapy. After a median follow-up of 16.2 months, ORR and complete response (CR) rate were 48.3% and 31.7%, respectively. Responses were similar across prior CAR-T products and time to relapse on CAR-T therapy. Median duration of response was 14.8 months and median duration of CR was not reached. Median progression-free survival and overall survival were 4.8 and 10.2 months, respectively. The most common treatment-emergent adverse event was cytokine release syndrome (48.3%; no grade ≥3 events). No cases of immune effector cell–associated neurotoxicity syndrome were reported. Grade ≥3 infections occurred in 12 patients (20.0%), 2 of which were COVID-19. Odronextamab monotherapy demonstrated encouraging efficacy and generally manageable safety, supporting its potential as an off-the-shelf option for patients after CAR-T therapy. This trial was registered at www.clinicaltrials.gov as #NCT02290951.
Impact of smoking on the detection of brain aneurysms in general population screening: a systematic review and meta-analysis
Ghoche, Maged T. , Maroufi, Seyed Farzad , Maalouf, Jorge Fouad , Pachón-Londoño, María José , Nguyen, Brandon , Halpin, Brooke S. , Turcotte, Evelyn L. , Patra, Devi P. , Krishna, Chandan , Turkmani, Ali , Ogilvy, Christopher S., Ogilvy, Christopher S. , Patra, Devi, Ogilvy, Christopher S , Maalouf, Joy M. El, Wang, Zhen , Bendok, Bernard R.

Mayo Clinic

Journal of Neurosurgery | December 27, 2024 | Volume: 142 | Issue: 5 | Pages: 1397-1405

10.3171/2024.7.jns241015 | PMID 39729618 Get It

OBJECTIVE While the relationship between smoking and subarachnoid hemorrhage is well established, data regarding the probability of detecting unruptured intracranial aneurysms (UIAs) in smokers remain sparse. The aim of this systematic review and meta-analysis is to provide a comprehensive understanding of the relationship between smoking and the likelihood of identifying UIAs in healthy asymptomatic patients who underwent brain imaging for indications unrelated to UIAs. METHODS A systematic review was conducted following the PRISMA guidelines. The PubMed and Scopus databases were searched for studies published before March 2024 that reported on the presence of UIAs in healthy asymptomatic patients who had undergone brain imaging for indications unrelated to UIAs. Three independent reviewers assessed the eligibility of all retrieved studies. Risk of bias for the included observational studies was assessed using the methodological index for non-randomized studies. Data on UIA prevalence, smoking status, and patient and aneurysm characteristics were extracted. The association between smoking and the presence of UIA was studied. A prevalence proportional meta-analysis was conducted across the included studies. A meta-analysis was performed with a random-effects model by using summary statistics from the included studies. RESULTS Six studies involving 47,788 patients who had undergone brain imaging were identified for quantitative analysis. The pooled UIA prevalence in the sample was 3.07% (95% CI 2.27%–4.16%). Patients who smoked had higher rates of aneurysm detection than the patients who did not smoke (pooled prevalence of 2.96%, 95% CI 2.68%–3.27% vs 2.23%, 95% CI 2.08%–2.39%). Although the relation between the two was not statistically significant (p = 0.06), smoking was associated with higher odds for UIA detection, yielding an OR of 1.34 (95% CI 1.07–1.67) with an I 2 value of 53%. CONCLUSIONS This study suggests a potentially higher risk of UIAs in patients who smoked than in those who never smoked. However, the results of this meta-analysis revealed that smoking was not statistically associated with higher UIA detection. This result could be explained by the limited number of studies published on this topic. If these findings reach statistical significance in future larger studies, it could justify revising guidelines to include cigarette smokers in intracranial aneurysm screening.
Impact of Anemia on Clinical Outcomes in Atrial Fibrillation Patients on Oral Anticoagulants: A Prognostic Meta‐Analysis
Amin, Ahmed Mazen , Elbenawi, Hossam , Odat, Ramez M. , Elgebaly, Mohamed , Al‐Shammari, Ali Saad , Manasrah, AlMothana , Nakhla, Michael , Ayman, Dina , Ali, Mohamed Ahmed , Helmi, Ahmed , Ternes, Caique M. P. , Zeb, Irfan , Deshmukh, Abhishek , Abuelazm, Mohamed , Ternes, Caique M P , Abdelazeem, Basel , Zeb, Irfan , Deshmukh, Abhishek J , DeSimone, Christopher V , d'Avila, Andre , Odat, Ramez M , Al-Shammari, Ali Saad , Ali, Mohamed Ahmed , Abuelazm, Mohamed , Abdelazeem, Basel , DeSimone, Christopher V.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | December 24, 2024 | Volume: 36 | Issue: 2 | Pages: 430-448

10.1111/jce.16537 | PMID 39716396 Get It

ABSTRACTBackgroundAnemia is frequently observed as a comorbidity in atrial fibrillation (AF), especially in elderly patients and in those on anticoagulation. This has been associated with poor clinical outcomes. We aim to investigate the impact of anemia on clinical outcomes in patients with AF on oral anticoagulation.MethodsWe comprehensively searched PubMed, WOS, SCOPUS, EMBASE, and CENTRAL through March 2024 and conducted a prognostic systematic review and meta‐analysis. All analyses were performed using R V. 4.3.1. This meta‐analysis was registered at PROSPERO (CRD42024556023).ResultsWe included 23 studies comprising 286,781 patients for analysis. Anemia had a significant association with an 84% increase in risk of major bleeding (HR: 1.84 with 95% CI [1.59, 2.13], p < 0.01), a 32% increase in the risk of intracranial hemorrhage (HR: 1.32 with 95% CI [1.10, 1.58], p < 0.01), a 98% increase in the risk of gastrointestinal bleeding (HR: 1.98 with 95% CI [1.67, 2.35], p < 0.01), and a 91% increase in the risk of all‐cause mortality (HR: 1.91 with 95% CI [1.46, 2.51], p < 0.01). However, the impact of anemia did not significantly affect the risk of stroke, transient ischemic stroke (TIA), or systemic embolism (HR: 1.07 with 95% CI [0.93, 1.22], p = 0.36).ConclusionAnemia was significantly associated with an increased risk of major bleeding, intracranial hemorrhage, gastrointestinal bleeding, and all‐cause mortality. However, anemia did not significantly impact stroke, TIA, or systemic embolism.
Fenestrated and Branched Endovascular Aortic Repair and Mortality at Hospitals Without Investigational Device Trials
Dun, Chen , Columbo, Jesse A. , Mendes, Bernardo C. , Goodney, Phillip, Schanzer, Andres, Schermerhorn, Marc L. , Makary, Martin A. , Black, James H. , Columbo, Jesse A , Zettervall, Sara L , Schanzer, Andres , Hicks, Caitlin W.

Mayo Clinic

JAMA Surgery | December 23, 2024 | Volume: 160 | Issue: 2 | Pages: 153

10.1001/jamasurg.2024.5654 | PMID 39714886 Get It

ImportanceFenestrated and branched endovascular aortic repairs (F/BEVAR) have been adopted by many centers. However, national trends of F/BEVAR use remain unclear, particularly at sites who perform them without an US Food and Drug Adminstration (FDA)–approved investigational device exemption (IDE).ObjectiveTo quantify the use of F/BEVAR in the US and to determine if mortality was different at IDE vs non-IDE sites.Design, Setting, and ParticipantsThis retrospective cohort study examined 100% fee-for-service Medicare claims data from 2016 to 2023. Participants were patients who underwent endovascular treatment of the visceral aorta incorporating 2 or more visceral artery endoprostheses. Hospitals with vs without an IDE were identified using hospitals’ Employer Identification Number as a time varying exposure.ExposureF/BEVAR.Main Outcomes and MeasuresTrends in the center-level F/BEVAR case volume stratified by IDE status were assessed using cumulative incidence curves. Mortality outcomes at 30 days and 3 years were compared using Kaplan-Meier methods and Cox proportional hazards models with adjustment for baseline patient characteristics.ResultsFrom 2016 to 2023, 8017 patients were treated with F/BEVAR at 549 hospitals. The median (IQR) age was 75.8 (71.3-80.8) years; 5795 patients (72.3%) were male and 2222 (27.7%) female. A total of 2226 F/BEVAR (27.8%) were performed at 22 hospitals with an IDE. The number of patients treated with F/BEVAR increased from 771 in 2016 to 1251 in 2023. The median (IQR) annual case volume per hospital was significantly higher at IDE sites (22.3 [11.0-30.4] vs 1.2 [1.0-2.0] cases/y; P &amp;lt; .001); 18 IDE sites (90.0%) and 20 non-IDE sites (3.7%) completed 9 or more cases per year. The 30-day mortality (3.0% vs 4.9%) but not 3-year mortality (26.0% vs 27.1%) was lower for patients treated at hospitals with vs without an IDE. After risk adjustment, both 30-day (odds ratio, 0.47; 95% CI, 0.32-0.69) and midterm mortality (hazard ratio, 0.81; 95% CI, 0.69-0.95) were lower for patients treated at IDE sites.Conclusions and RelevanceThe use of F/BEVAR is increasing across the United States, with the majority of cases being performed outside of IDE studies and at low-volume centers. F/BEVAR performed at non-IDE centers are associated with higher adjusted 30-day and midterm mortality. Transparent outcome reporting and identification of process measures from IDE sites may help achieve more equity in patient outcomes.
Gut Microbiome Modulation of Glutamate Dynamics: Implications for Brain Health and Neurotoxicity
Gruenbaum, Benjamin F. , Merchant, Kiran S. , Boyko, Matthew , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Merchant, Kiran S , Zlotnik, Alexander Anatolievich

Mayo Clinic

Nutrients | December 23, 2024 | Volume: 16 | Issue: 24 | Pages: 4405

10.3390/nu16244405 | PMID 39771027 Get It

The gut–brain axis plays an integral role in maintaining overall health, with growing evidence suggesting its impact on the development of various neuropsychiatric disorders, including depression. This review explores the complex relationship between gut microbiota and glutamate (Glu) regulation, highlighting its effect on brain health, particularly in the context of depression following certain neurological insults. We discuss how microbial populations can either facilitate or limit Glu uptake, influencing its bioavailability and predisposing to neuroinflammation and neurotoxicity. Additionally, we examine the role of gut metabolites and their influence on the blood–brain barrier and neurotransmitter systems involved in mood regulation. The therapeutic potential of microbiome-targeted interventions, such as fecal microbiota transplantation, is also highlighted. While much research has explored the role of Glu in major depressive disorders and other neurological diseases, the contribution of gut microbiota in post-neurological depression remains underexplored. Future research should focus on explaining the mechanisms linking the gut microbiota to neuropsychiatric outcomes, particularly in conditions such as post-stroke depression, post-traumatic brain-injury depression, and epilepsy-associated depression. Systematic reviews and human clinical studies are needed to establish causal relationships and assess the efficacy of microbiome-targeted therapies in improving the neuropsychiatric sequalae after neurological insults.
Implementing the 2024 ACC/AHA Multisocietal PAD guidelines into clinical practice: Key changes from the 2016 guidelines
Cohoon, Kevin P. , Henkin, Stanislav , Tomihama, Roger T. , Thomas, Sneha , Porres‐Aguilar, Mateo , Brunton, Nichole , Hornacek, Deborah , Secemsky, Eric A. , Brunton, Nichole E , Porres-Aguilar, Mateo , Tomihama, Roger , Henkin, Stanislav , Secemsky, Eric A

Mayo Clinic

Vascular Medicine | December 23, 2024 | Volume: 30 | Issue: 1 | Pages: 110-113

10.1177/1358863x241306354 | PMID 39713878 Get It